Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors

Mingxiang Liao, Simon P. Watkins, Eileen Nash, Jeff Isaacson, Jeff Etter, Jeri Beltman, Rong Fan, Li Shen, Abdul Mutlib, Vendel Kemény, Zsuzsanna Pápai, Pascal van Tilburg, Jim XiaoInvestigational 2019 · DOI

Abstract

Rucaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of recurrent ovarian, fallopian tube, and primary peritoneal cancers. This study characterized the absorption, distribution, metabolism, and elimination (ADME) of rucaparib in six patients with advanced solid tumors following a single 600 mg oral dose of [14C]-rucaparib. Total radioactivity (TRA) and unchanged rucaparib were tracked in blood, plasma, urine, and feces. Results showed a mean recovery of 89.3% of the dose over 12 days, with feces being the primary route of elimination (71.9%). Rucaparib and its oxidative metabolite, M324, were the major components identified. These findings suggest that rucaparib is cleared through multiple redundant pathways, including hepatic metabolism and renal/biliary excretion.

Introduction

Understanding the pharmacokinetic (PK) "budget" of a therapeutic agent is essential for clinical safety, particularly for predicting drug-drug interactions and adjusting dosages for patients with renal or hepatic impairment. Rucaparib, an FDA-approved therapy for BRCA-mutated cancers, requires a clear map of its metabolic breakdown and clearance organs. This study provides the first published human mass balance for rucaparib, accounting for the drug's complete journey through the body to ensure optimal clinical use.

Methods

In this Phase I, open-label study, six female patients with advanced solid tumors received a single oral 600 mg dose of rucaparib containing approximately 140 μCi of [14C]-radioactivity. Total Radioactivity (TRA) was measured in biological samples over a 12-day period using Liquid Scintillation Counting (LSC). Unchanged rucaparib and its metabolites were quantified and identified using validated LC-MS/MS and Orbitrap mass spectrometry. Pharmacokinetic parameters were calculated via non-compartmental analysis.

Results

Pharmacokinetics and Plasma Distribution

Rucaparib was absorbed with a median peak plasma concentration ($C_{max}$) occurring at approximately 4 hours post-dose. The terminal half-life for both TRA and unchanged rucaparib exceeded 25 hours, supporting the current clinical twice-daily dosing schedule. The blood-to-plasma ratio of radioactivity was approximately 1.0 at $C_{max}$, indicating an even distribution between plasma and red blood cells.

Mean concentration-time profiles of total radioactivity and rucaparib in plasma and blood.

As shown in the concentration-time profiles, the curves for TRA and unchanged rucaparib were parallel, suggesting that metabolites are formed and cleared at rates similar to the parent drug. The higher concentration of TRA compared to rucaparib in plasma confirms the presence of circulating metabolites.

Excretion and Mass Balance

The study achieved a high degree of mass balance, with a mean total recovery of 89.3% of the radioactive dose. Fecal excretion was the dominant pathway, accounting for 71.9% of the dose, while renal excretion accounted for 17.4%.

Cumulative recovery of total radioactivity in urine and feces over 288 hours.

The high fecal recovery is attributed to a combination of unabsorbed drug and biliary excretion of absorbed drug. In feces, rucaparib remained largely unchanged (63.9% of dose), whereas in urine, rucaparib and the metabolite M324 were the primary components (each ~7.6% of dose).

Metabolism

Metabolic profiling identified M324, an oxidative metabolite, as the primary breakdown product. In plasma, rucaparib accounted for 64.0% of the radioactivity, while M324 contributed 18.6%. The study confirms that rucaparib is cleared through redundant pathways involving CYP-mediated hepatic metabolism, renal filtration, and biliary excretion.

Discussion and Limitations

This study successfully mapped the ADME profile of rucaparib, highlighting its multi-pathway clearance. While the small sample size (n=6) is standard for human radiolabeled studies, it may not capture full inter-patient variability across different demographics. Additionally, while fecal excretion is the major route, the exact proportion of unabsorbed drug versus biliary-excreted drug remains to be precisely quantified. Future research will continue to evaluate the clinical impact and specific PK profile of the M324 metabolite.

Summary updated

Abstract

Rucaparib, a poly(ADP-ribose) polymerase inhibitor, is licensed for use in recurrent ovarian, fallopian tube, or primary peritoneal cancer. We characterized the absorption, distribution, metabolism, and elimination of rucaparib in 6 patients with advanced solid tumors following a single oral dose of [<sup>14</sup>C]-rucaparib 600 mg (≈140 μCi). Total radioactivity (TRA) in blood, plasma, urine, and feces was measured using liquid scintillation counting. Unchanged rucaparib concentrations in plasma were determined using validated liquid chromatography with tandem mass spectrometry. Maximum concentration (C<sub>max</sub>) of TRA and unchanged rucaparib in plasma was 880 ng Eq/mL and 428 ng/mL, respectively, at approximately 4 h post dose; terminal half-life was >25 h for both TRA and rucaparib. The plasma TRA-time profile was parallel to yet higher than that of rucaparib, suggesting the presence of metabolites in plasma. Mean blood:plasma ratio of radioactivity was 1.0 for C<sub>max</sub> and 0.8 for area under the concentration-time curve from time zero to infinity. Mean postdose recovery of TRA was 89.3% over 12 days (71.9% in feces; 17.4% in urine). Unchanged rucaparib and M324 (oxidative metabolite) were the major components in plasma, contributing to 64.0% and 18.6% of plasma radioactivity, respectively. Rucaparib and M324 were the major rucaparib-related components (each ≈7.6% of dose) in urine, whereas rucaparib was the predominant component (63.9% of dose) in feces. The high fecal recovery of unchanged rucaparib could be attributed to hepatic excretion and/or incomplete oral absorption. Overall, these data suggest that rucaparib is eliminated through multiple pathways, including metabolism and renal and biliary excretion.
BibTeX
@inproceedings{liao2019evaluation,
  author = {Mingxiang Liao and Simon P. Watkins and Eileen Nash and Jeff Isaacson and Jeff Etter and Jeri Beltman and Rong Fan and Li Shen and Abdul Mutlib and Vendel Kemény and Zsuzsanna Pápai and Pascal van Tilburg and Jim Xiao},
  title = {{Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors}},
  booktitle = {Investigational},
  year = {2019},
  doi = {10.1007/s10637-019-00815-2},
}
Figure